1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Influenzavirus B Infections - Pipeline Review, H2 2020, provides an overview of the Influenzavirus B Infections (Infectious Disease) pipeline landscape.
Type B influenza is a subtype of the influenza virus that tends to occur sporadically. Symptoms include runny nose, sore throat, aching muscles, malaise, watery eyes, aching body, loss of appetite and weakness. Treatment includes antiviral, analgesics and antipyretics medications.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Influenzavirus B Infections - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Influenzavirus B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Influenzavirus B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenzavirus B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 7, 9, 4, 6, 23 and 6 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 4, 1 and 1 molecules, respectively.
Influenzavirus B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenzavirus B Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenzavirus B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenzavirus B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenzavirus B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenzavirus B Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenzavirus B Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenzavirus B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionInfluenzavirus B Infections - Overview
Influenzavirus B Infections - Therapeutics Development
Influenzavirus B Infections - Therapeutics Assessment
Influenzavirus B Infections - Companies Involved in Therapeutics Development
Influenzavirus B Infections - Drug Profiles
Influenzavirus B Infections - Dormant Projects
Influenzavirus B Infections - Discontinued Products
Influenzavirus B Infections - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Influenzavirus B Infections, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Influenzavirus B Infections - Pipeline by AbbVie Inc, H2 2020
- Influenzavirus B Infections - Pipeline by Abhelix LLC, H2 2020
- Influenzavirus B Infections - Pipeline by Adimmune Corp, H2 2020
- Influenzavirus B Infections - Pipeline by Allergy Therapeutics Plc, H2 2020
- Influenzavirus B Infections - Pipeline by Ansun Biopharma Inc, H2 2020
- Influenzavirus B Infections - Pipeline by Aphios Corp, H2 2020
- Influenzavirus B Infections - Pipeline by AstraZeneca Plc, H2 2020
- Influenzavirus B Infections - Pipeline by AusBio Ltd, H2 2020
- Influenzavirus B Infections - Pipeline by Biotron Ltd, H2 2020
- Influenzavirus B Infections - Pipeline by BlueWillow Biologics Inc, H2 2020
- Influenzavirus B Infections - Dormant Projects, H2 2020
- Influenzavirus B Infections - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Influenzavirus B Infections, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Routes of Administration, H2 2020
- Number of Products by Stage and Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Abhelix LLC
- Adimmune Corp
- Allergy Therapeutics Plc
- Ansun Biopharma Inc
- Aphios Corp
- AstraZeneca Plc
- AusBio Ltd
- Biotron Ltd
- BlueWillow Biologics Inc
- Cidara Therapeutics Inc
- Cocrystal Pharma Inc
- ContraFect Corp
- CSL Ltd
- e-Therapeutics Plc
- Evotec SE
- Evrys Bio
- FUJIFILM Toyama Chemical Co Ltd
- GC Pharma
- Ginkgo Tree Pharmaceutical (Suzhou) Co Ltd
- Imutex Ltd
- Inovio Pharmaceuticals Inc
- iQur Ltd
- Jiangsu Ab&b Biotechnology Co Ltd
- Jiangsu Carephar Pharmaceutical Co Ltd
- Johnson & Johnson
- Kentucky BioProcessing LLC
- Medicago Inc
- Novavax Inc
- Osivax SAS
- Park Active Molecules
- Pentavalent Bio Sciences Pvt Ltd
- Romark Laboratories LC
- SAB Biotherapeutics Inc
- Sanofi
- Sciogen Inc
- Seqirus Ltd
- Serum Institute of India Ltd
- Shanghai Institute of Biological Products Co Ltd
- Shionogi & Co Ltd
- TaiGen Biotechnology Co Ltd
- Therapeutic Systems Research Laboratories Inc
- Trellis Bioscience Inc
- Tria Bioscience Corp
- UMN Pharma Inc
- Vacthera BioTech GmbH
- Ventaleon GmbH
- Viramatix Sdn Bhd
- Wuhan Institute of Biological Products Co Ltd
